Page 140 - Merck Sharp News Today

Editas Medicine Names Mark S. Shearman, Ph.D., as Chief Scientific Officer May 05, 2021 06:59 ET | Source: Editas Medicine, Inc. Editas Medicine, Inc. Cambridge, Massachusetts, UNITED STATES CAMBRIDGE, Mass., May 05, 2021 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a leading genome editing company, today announced that it named Mark S. Shearman, Ph.D., as the Company’s Executive Vice President and Chief Scientific Officer. Dr. Shearm...

shutterstock.com The U.S. District Court for the Eastern District of Pennsylvania reported the following activity on April 26 in the suits below: In United Financial Casualty Company: Notice Of Removal By United Financial Casualty Company (filing Fee $ 402 Receipt Number 0313-15077642), Filed By United Financial Casualty Company. (attachments: # 1 Civil Cover Sheet, # 2 Designation Form, # 3 Case Management Track Form)(carter, Beth) Disclosure Statement Form Pursuant To...

The impact of coronavirus pandemic on the global Antidiabetics market has proved to be quite positive. Unavailability of cure for diabetes and vulnerability of diabetic patients to COVID-19 has enhanced the demand for anti-diabetic drugs across the global. The key players of the market are predicted to unleash myriads of opportunities for the growth of the market in the forthcoming years by their smart strategies. The recently published research report by Research Dive reflects on the influence...

Erdafitinib (Janssen Research and Development). The anticipated launch of targeted therapies including potential FGFR gene fusions and somatic mutations in IDH 1/2 in iCCA, PRKACA or PRKACB gene fusions in pCCA, and ELF3 mutations in dCCA/ampullary carcinoma shall push the growth of the BTC market size in the offing.  Further, an increase in the BTC incidence, increment in healthcare spending, extensive R&D along better awareness of cancer is expected to give the BTC market size growth a muc...

COVID-19 treatment: 5 Indian drugmakers ink pacts with Merck for molnupiravir The company, known as Merck in the US and Canada, has inked pacts with Cipla, Dr Reddys Laboratories, Sun Pharma, Hetero Labs, and Emcure Pharmaceuticals BusinessToday.In | April 28, 2021 | Updated 12:19 IST MSD India is a wholly-owned subsidiary of Merck Sharp & Dohme (MSD) Drug firm MSD announced on Tuesday its decision to enter into voluntary licencing agreements with five Indian generic manufacturers to supply it...

/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the first quarter of 2021. "Our first quarter results reflect solid execution...

Merck & Co. Inc. and Merck Sharp & Dohme Corp.: Complaint Against All Defendants ( Filing Fee $ 402 Receipt Number 0313-15064138.), Filed By Joyce Dworsky, George Dworsky. (attachments: # 1 Civil Cover Sheet Civil Cover Sheet, # 2 Certificate Of Service Merck & Co. Inc. /pos, # 3 Certificate Of Service McKesson Corp./pos, #4 Certificate Of Service Merck Sharp And Dohme Corp./Pos, # 5 Case Management Track Form Case Management Track Form, # 6 Designation Form Designation Form)(humphrey, Debra) ...

Search jobs Global Heart Failure Drugs Market to Witness the Highest Growth Globally In Coming Years A careful and transparent research studies conducted by a team of experts in their own domain gets this global Global Heart Failure Drugs Market research report done efficiently. Best practice models and research methodologies are executed in this report to give comprehensive market analysis with accurate market segmentation and insights. This report also offers such wi...

- Two Posters to Include Data Updates From ARTISTRY-1 and ARTISTRY-2 Clinical Trials Evaluating Immuno-Oncology Candidate Nemvaleukin Alfa - DUBLIN, April 28, 2021 /PRNewswire/ -- Alkermes

MSD widens access to molnupiravir in India MSD widens access to molnupiravir in India 27 April 2021 | News Image credit- shutterstock.com MSD Pharmaceuticals, a wholly owned subsidiary of Merck Sharp & Dohme and known as Merck & Co., Inc., in the United States and Canada, has announced that the company has decided to enter into non-exclusive voluntary licensing agreements for molnupiravir with five established Indian generic manufacturers. Molnupiravir is an investigational oral antiviral agen...